Skip to main content
Erschienen in: Rheumatology International 7/2018

17.05.2018 | Cases with a Message

Improvement of neurological and ocular symptoms of Behçet’s disease after the introduction of infliximab

verfasst von: Marko Barešić, Mirna Reihl, Mario Habek, Nenad Vukojević, Branimir Anić

Erschienen in: Rheumatology International | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Behçet’s disease is a chronic inflammatory condition of unknown origin characterized by multiple organ involvement. The most common symptoms of Behçet’s disease are recurrent oral and/or genital ulcerations in combination with symptoms affecting eyes, skin, central and peripheral nervous system, blood vessels and gastrointestinal tract. We present a 43-year-old female patient with the history of recurrent episodes of genital and oral ulcerations, elevated acute phase reactants and skin lesions. The diagnosis of Behçet’s disease has been delayed (for more than 10 years) and reached only after she developed neurological and ocular symptoms. Treatment with glucocorticoids and azathioprine was partially successful. High doses of glucocorticoids were needed to control the disease and cyclosporine A was nephrotoxic. Remission was reached after the introduction of infliximab (plus methotrexate) and glucocorticoids were stopped. In the recent years, infliximab has been accepted as a standard therapy for refractory cases of Behçet’s disease (neurological, ocular or gastrointestinal). Our patient presented with refractory ocular and neurological symptoms and infliximab was effective for both manifestations. Long-term side-effects of glucocorticoids and other immunosuppressants can be avoided with TNF-α blockade. We emphasize the importance of a timely and accurate diagnosis and significance of excluding more common diseases in a work-up algorithm.
Literatur
1.
Zurück zum Zitat Yazici Y, Yurdakul S, Yazici H (2010) Behçet’s syndrome. Curr Rheumatol Rep 12(6):429–435CrossRefPubMed Yazici Y, Yurdakul S, Yazici H (2010) Behçet’s syndrome. Curr Rheumatol Rep 12(6):429–435CrossRefPubMed
2.
Zurück zum Zitat Papoutsis NG, Abdel-Naser MB, Altenburg A, Orawa H, Kötter I, Krause L et al (2006) Prevalence of Adamantiades-Behçet’s disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 24(5 Suppl 42):S125PubMed Papoutsis NG, Abdel-Naser MB, Altenburg A, Orawa H, Kötter I, Krause L et al (2006) Prevalence of Adamantiades-Behçet’s disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 24(5 Suppl 42):S125PubMed
3.
Zurück zum Zitat Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M et al (2010) Behcet’s disease: from East to West. Clin Rheumatol 29(8):823–833CrossRefPubMed Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M et al (2010) Behcet’s disease: from East to West. Clin Rheumatol 29(8):823–833CrossRefPubMed
4.
Zurück zum Zitat Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O et al (2008) Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 58(12):3951–3959CrossRefPubMed Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O et al (2008) Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 58(12):3951–3959CrossRefPubMed
5.
Zurück zum Zitat Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M et al (2003) Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol 42(10):803–806CrossRefPubMed Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M et al (2003) Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol 42(10):803–806CrossRefPubMed
6.
Zurück zum Zitat Seaman G, Pearce RA (1997) Behcet’s disease manifestation in a population drawn from the UK Behcet’s syndrome society. In: Hamza M (ed). Behcet’s Disease, Pub Adhoua, Tunisia. pp 196–199 Seaman G, Pearce RA (1997) Behcet’s disease manifestation in a population drawn from the UK Behcet’s syndrome society. In: Hamza M (ed). Behcet’s Disease, Pub Adhoua, Tunisia. pp 196–199
8.
Zurück zum Zitat International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet Lond Engl 335(8697):1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet Lond Engl 335(8697):1078–1080
10.
Zurück zum Zitat Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H et al (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20(9):1544–1549PubMed Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H et al (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20(9):1544–1549PubMed
11.
Zurück zum Zitat Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T et al (2003) Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine 24(5):210–218CrossRefPubMed Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T et al (2003) Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine 24(5):210–218CrossRefPubMed
12.
Zurück zum Zitat El-Asrar AMA, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K et al (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol Orlando Fla 139(2):177–184CrossRef El-Asrar AMA, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K et al (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol Orlando Fla 139(2):177–184CrossRef
13.
Zurück zum Zitat Mochizuki M, Akduman L, Nussenblatt R. Behc¸et’s disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds). Ocular infection and immunity. St Louis: Mosby. 1996;663–675 Mochizuki M, Akduman L, Nussenblatt R. Behc¸et’s disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds). Ocular infection and immunity. St Louis: Mosby. 1996;663–675
14.
Zurück zum Zitat Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J et al (2010) Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 248(5):709–714CrossRefPubMed Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J et al (2010) Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 248(5):709–714CrossRefPubMed
15.
Zurück zum Zitat Theodossiadis PG, Markomichelakis NN, Sfikakis PP (2007) Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina Phila Pa 27(4):399–413CrossRef Theodossiadis PG, Markomichelakis NN, Sfikakis PP (2007) Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina Phila Pa 27(4):399–413CrossRef
17.
Zurück zum Zitat Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I (2012) Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segmentuveitis: a prospective, follow-up study of 50 patients. Biologics 6:5–12PubMed Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I (2012) Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segmentuveitis: a prospective, follow-up study of 50 patients. Biologics 6:5–12PubMed
18.
Zurück zum Zitat Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet’s Disease Research Group Of Japan (2012) Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol Chic Ill 1960 130(5):592–598CrossRef Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet’s Disease Research Group Of Japan (2012) Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol Chic Ill 1960 130(5):592–598CrossRef
19.
Zurück zum Zitat Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM (2013) Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocul Immunol Inflamm 21(6):468–474CrossRefPubMed Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM (2013) Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocul Immunol Inflamm 21(6):468–474CrossRefPubMed
20.
Zurück zum Zitat Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541.e1CrossRefPubMed Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541.e1CrossRefPubMed
21.
Zurück zum Zitat Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122:2171–2182CrossRefPubMed Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122:2171–2182CrossRefPubMed
22.
Zurück zum Zitat Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67(12):1656–1662CrossRefPubMed Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67(12):1656–1662CrossRefPubMed
24.
Zurück zum Zitat Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41(1):61–70CrossRefPubMed Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41(1):61–70CrossRefPubMed
25.
Zurück zum Zitat Neves FS, Ferreira RM, Pereira IA, Zimmermann AF, Lin K (2013) Neuro-Behçet’s disease, its mimickers and anti-TNF therapy: a case-based review. Clin Exp Rheumatol. 31:133–140PubMed Neves FS, Ferreira RM, Pereira IA, Zimmermann AF, Lin K (2013) Neuro-Behçet’s disease, its mimickers and anti-TNF therapy: a case-based review. Clin Exp Rheumatol. 31:133–140PubMed
26.
Zurück zum Zitat Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45(2):55–57CrossRefPubMed Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45(2):55–57CrossRefPubMed
27.
Zurück zum Zitat Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381–387CrossRefPubMed Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381–387CrossRefPubMed
28.
Zurück zum Zitat Wallis RS (2009) Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 22(4):403–409CrossRefPubMed Wallis RS (2009) Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 22(4):403–409CrossRefPubMed
29.
Zurück zum Zitat Abalos-Medina GM, Sánchez-Cano D, Ruiz-Villaverde G, Ruiz-Villaverde R, Quirosa Flores S, Raya Alvarez E (2009) Successful use of infliximab in a patient with neuro-Behçet’s disease. Int J Rheum Dis 12(3):264–266CrossRefPubMed Abalos-Medina GM, Sánchez-Cano D, Ruiz-Villaverde G, Ruiz-Villaverde R, Quirosa Flores S, Raya Alvarez E (2009) Successful use of infliximab in a patient with neuro-Behçet’s disease. Int J Rheum Dis 12(3):264–266CrossRefPubMed
30.
Zurück zum Zitat Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S (2011) Infliximab for patients with neuro-Behcet’s disease: case series and literature review. Clin Rheumatol 30(7):1007–1012CrossRefPubMed Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S (2011) Infliximab for patients with neuro-Behcet’s disease: case series and literature review. Clin Rheumatol 30(7):1007–1012CrossRefPubMed
31.
Zurück zum Zitat Studer U, Ruehe B, Waldegg G, Vajtai I, Escher R, Aeberli D (2012) Atypical presentation of Behçet’s disease with central nervous system involvement successfully treated with infliximab. Rheumatol Int 32(5):1431–1435CrossRefPubMed Studer U, Ruehe B, Waldegg G, Vajtai I, Escher R, Aeberli D (2012) Atypical presentation of Behçet’s disease with central nervous system involvement successfully treated with infliximab. Rheumatol Int 32(5):1431–1435CrossRefPubMed
32.
Zurück zum Zitat Kanemaru H, Makino T, Jinnin M, Yonemitsu A, Makino K, Ihn H (2013) Case of neuro-Behçet’s disease successfully maintained a remission using infliximab for 2 years. J Dermatol 40(8):632–634CrossRefPubMed Kanemaru H, Makino T, Jinnin M, Yonemitsu A, Makino K, Ihn H (2013) Case of neuro-Behçet’s disease successfully maintained a remission using infliximab for 2 years. J Dermatol 40(8):632–634CrossRefPubMed
33.
Zurück zum Zitat Filippo MD, Gregorio MD, Nannini C, Gaetani L, Gallina C, Floridi P et al (2014) Infliximab monotherapy for neuro-Behçet’s disease: a case report. J Neurol Sci 347(1):389–390CrossRefPubMed Filippo MD, Gregorio MD, Nannini C, Gaetani L, Gallina C, Floridi P et al (2014) Infliximab monotherapy for neuro-Behçet’s disease: a case report. J Neurol Sci 347(1):389–390CrossRefPubMed
34.
Zurück zum Zitat Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K et al (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95(24):e3863CrossRef Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K et al (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95(24):e3863CrossRef
35.
Zurück zum Zitat Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S et al (2016) Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflammation 3(5):e258CrossRef Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S et al (2016) Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflammation 3(5):e258CrossRef
36.
Zurück zum Zitat Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci 272(1–2):99–105CrossRefPubMed Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci 272(1–2):99–105CrossRefPubMed
37.
Zurück zum Zitat Jalili A, Kinaciyan T, Barisani T, Peck-Radosavljevic M, Stingl G, Geusau A et al (2009) Successful treatment of refractory Behçet’s disease with the TNF-alpha blocker infliximab. Iran J Immunol IJI 6(1):55–58PubMed Jalili A, Kinaciyan T, Barisani T, Peck-Radosavljevic M, Stingl G, Geusau A et al (2009) Successful treatment of refractory Behçet’s disease with the TNF-alpha blocker infliximab. Iran J Immunol IJI 6(1):55–58PubMed
38.
Zurück zum Zitat Donghi D, Mainetti C (2010) Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement. Dermatol Basel Switz 220(3):282–286CrossRef Donghi D, Mainetti C (2010) Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement. Dermatol Basel Switz 220(3):282–286CrossRef
39.
Zurück zum Zitat Karube H, Kamoi K, Ohno-Matsui K (2016) Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet’s disease. Int Med Case Rep J 9:301–304CrossRefPubMedPubMedCentral Karube H, Kamoi K, Ohno-Matsui K (2016) Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet’s disease. Int Med Case Rep J 9:301–304CrossRefPubMedPubMedCentral
Metadaten
Titel
Improvement of neurological and ocular symptoms of Behçet’s disease after the introduction of infliximab
verfasst von
Marko Barešić
Mirna Reihl
Mario Habek
Nenad Vukojević
Branimir Anić
Publikationsdatum
17.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 7/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4054-9

Weitere Artikel der Ausgabe 7/2018

Rheumatology International 7/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.